Search by Drug Name or NDC
NDC 00517-2502-10 Caffeine and Sodium Benzoate 125 mg/mL Details
Caffeine and Sodium Benzoate 125 mg/mL
Caffeine and Sodium Benzoate is a INTRAMUSCULAR; INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by American Regent, Inc.. The primary component is CAFFEINE.
Product Information
| NDC | 00517-2502 |
|---|---|
| Product ID | 0517-2502_53245845-b446-46f8-bbe8-3323c58e10e5 |
| Associated GPIs | 61300010202010 |
| GCN Sequence Number | 019074 |
| GCN Sequence Number Description | caffeine/sodium benzoate VIAL 250 MG/ML INJECTION |
| HIC3 | A1B |
| HIC3 Description | XANTHINES |
| GCN | 54190 |
| HICL Sequence Number | 000010 |
| HICL Sequence Number Description | CAFFEINE/SODIUM BENZOATE |
| Brand/Generic | Generic |
| Proprietary Name | Caffeine and Sodium Benzoate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Caffeine and Sodium Benzoate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAMUSCULAR; INTRAVENOUS |
| Active Ingredient Strength | 125 |
| Active Ingredient Units | mg/mL |
| Substance Name | CAFFEINE |
| Labeler Name | American Regent, Inc. |
| Pharmaceutical Class | Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Methylxanthine [EPC], Xanthines [CS] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG OTHER |
| Application Number | n/a |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00517-2502-10 (00517250210)
| NDC Package Code | 0517-2502-10 |
|---|---|
| Billing NDC | 00517250210 |
| Package | 10 VIAL, SINGLE-DOSE in 1 BOX (0517-2502-10) / 2 mL in 1 VIAL, SINGLE-DOSE (0517-2502-01) |
| Marketing Start Date | 1993-02-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |